Data on the Impact on Hemoglobin Control Using a Software-Based
-- Abstract: Use of Epoetin Alfa in Maintaining Hemoglobin Control
Through a Software-Based Management Tool in a Community Nephrology
Craig Kleinmann, D.O., Nephrology Associates, Mobile, AL
A retrospective, observational chart review from a large U.S.
nephrology clinic was conducted in May 2007 to analyze the impact of
EPO on mean Hb over time as well as subsequent dose holds in anemic
non-dialysis CKD patients in a community practice setting using
TrakAnemia, a software-based tool. Eighty-seven patients who had a
documented diagnosis of anemia due to non-dialysis CKD, initiated EPO,
and had greater than or equal to six months of follow-up data were
included in the final analysis.
About PROCRIT (Epoetin alfa)
PROCRIT is used for the treatment of anemia in patients with most types of cancer receiving chemotherapy, with chronic renal failure who are on dialysis and those who are not on dialysis, who are being treated with zidovudine for HIV infection, and to reduce the need for transfusion in anemic patients who are scheduled for elective noncardiac, nonvascular surgery. Depending on the country in which Epoetin alfa is marketed, these indications may differ.
Important U.S. Safety Information for PROCRIT
Boxed WARNINGS: INCREASED MORTALITY, SERIOUS CARDIOVASCULAR and THROMBOEMBOLIC EVENTS, and TUMOR PROGRESSION
Renal failure: Patients experienced greater risks for death and serious
cardiovascular events when administered erythropoiesis-stimulating agents
(ESAs) to target higher versus lower hemoglobin levels (13.5 vs. 11.3 g/dL;
14 vs. 10 g/dL) in two clinical studies. Individualize dosing to achieve
and maintain hemoglobin levels within the range of 10 to 12 g/dL.
|SOURCE Ortho Biotech Products, L.P.|
Copyright©2008 PR Newswire.
All rights reserved